Atomoxetine Hydrochloride
Modify Date: 2024-01-01 23:33:57
Atomoxetine Hydrochloride structure
|
Common Name | Atomoxetine Hydrochloride | ||
|---|---|---|---|---|
| CAS Number | 82248-59-7 | Molecular Weight | 291.816 | |
| Density | N/A | Boiling Point | 389ºC at 760 mmHg | |
| Molecular Formula | C17H22ClNO | Melting Point | 167-169ºC | |
| MSDS | USA | Flash Point | 164.1ºC | |
| Symbol |
GHS02, GHS06, GHS08 |
Signal Word | Danger | |
Use of Atomoxetine HydrochlorideAtomoxetine Hcl(LY 139603; Tomoxetine Hcl) is a potent and selective noradrenalin re-uptake inhibitor (Ki values are 5, 77 and 1451 nM for inhibition of radioligand binding to human NET, SERT and DAT respectively). IC50 value: 5 nM (Ki for human NET)Target: NETAtomoxetine displays minimal affinity for a range of other neurotransmitter receptors and transporters (Ki > 1 μM). Atomoxetine is antidepressant and a commonly used non-stimulant treatment for Attention deficit hyperactivity disorder (ADHD). |
| Name | atomoxetine hydrochloride |
|---|---|
| Synonym | More Synonyms |
| Description | Atomoxetine Hcl(LY 139603; Tomoxetine Hcl) is a potent and selective noradrenalin re-uptake inhibitor (Ki values are 5, 77 and 1451 nM for inhibition of radioligand binding to human NET, SERT and DAT respectively). IC50 value: 5 nM (Ki for human NET)Target: NETAtomoxetine displays minimal affinity for a range of other neurotransmitter receptors and transporters (Ki > 1 μM). Atomoxetine is antidepressant and a commonly used non-stimulant treatment for Attention deficit hyperactivity disorder (ADHD). |
|---|---|
| Related Catalog | |
| References |
[5]. Atomoxetine |
| Boiling Point | 389ºC at 760 mmHg |
|---|---|
| Melting Point | 167-169ºC |
| Molecular Formula | C17H22ClNO |
| Molecular Weight | 291.816 |
| Flash Point | 164.1ºC |
| Exact Mass | 291.138977 |
| PSA | 21.26000 |
| LogP | 4.91750 |
| Storage condition | 2-8°C |
| Symbol |
GHS02, GHS06, GHS08 |
|---|---|
| Signal Word | Danger |
| Hazard Statements | H225-H301 + H311 + H331-H370 |
| Precautionary Statements | P210-P260-P280-P301 + P310-P311 |
| Personal Protective Equipment | Eyeshields;Gloves;type N95 (US);type P1 (EN143) respirator filter |
| Hazard Codes | F,T |
| Risk Phrases | 11-23/24/25-39/23/24/25 |
| Safety Phrases | S22-S24/25 |
| RIDADR | UN1230 - class 3 - PG 2 - Methanol, solution |
| WGK Germany | 3 |
| HS Code | 2922299090 |
| Precursor 9 | |
|---|---|
| DownStream 0 | |
CAS#:615-37-2
CAS#:115290-81-8
CAS#:105314-52-1
CAS#:83113-55-7
CAS#:1027094-45-6
CAS#:134619-78-6
CAS#:95-48-7
CAS#:74-89-5
CAS#:114446-47-8| HS Code | 2922299090 |
|---|---|
| Summary | 2922299090. other amino-naphthols and other amino-phenols, other than those containing more than one kind of oxygen function, their ethers and esters; salts thereof. VAT:17.0%. Tax rebate rate:13.0%. . MFN tariff:6.5%. General tariff:30.0% |
|
Methylphenidate and atomoxetine inhibit social play behavior through prefrontal and subcortical limbic mechanisms in rats.
J. Neurosci. 35(1) , 161-9, (2015) Positive social interactions during the juvenile and adolescent phases of life, in the form of social play behavior, are important for social and cognitive development. However, the neural mechanisms ... |
|
|
Atomoxetine prevents dexamethasone-induced skeletal muscle atrophy in mice.
J. Pharmacol. Exp. Ther. 351(3) , 663-73, (2014) Skeletal muscle atrophy remains a clinical problem in numerous pathologic conditions. β2-Adrenergic receptor agonists, such as formoterol, can induce mitochondrial biogenesis (MB) to prevent such atro... |
|
|
Current pharmacotherapy of attention deficit hyperactivity disorder.
Drugs Today (Barc) 49(10) , 647-65, (2013) Attention deficit hyperactivity disorder (ADHD) is a neurobehavioral developmental disorder in children and adults characterized by a persistent pattern of impulsiveness, inattention and hyperactivity... |
| Atomoxetine HCL |
| benzenepropanamine, N-methyl-γ-(2-methylphenoxy)-, (γR)-, hydrochloride |
| (gR)-N-Methyl-g-(2-methylphenoxy)benzenepropanamine Hydrochloride |
| (3R)-N-méthyl-3-(2-méthylphénoxy)-3-phénylpropan-1-amine chlorhydrate |
| MFCD06410992 |
| (3R)-N-Methyl-3-(2-methylphenoxy)-3-phenylpropan-1-amine hydrochloride (1:1) |
| Atomoxetine hydrochloride |
| EINECS 200-659-6 |
| (3R)-N-methyl-3-(2-methylphenoxy)-3-phenylpropan-1-amine hydrochloride |
| (3R)-N-Methyl-3-(2-methylphenoxy)-3-phenylpropan-1-aminhydrochlorid |
| (3R)-N-Methyl-3-(2-methylphenoxy)-3-phenyl-1-propanamine hydrochloride (1:1) |
| Benzenepropanamine, N-methyl-γ-(2-methylphenoxy)-, (γR)-, hydrochloride (1:1) |
| Atomoxetine (hydrochloride) |